サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1133510

マラリアワクチンの世界市場-2022-2029

Global Malaria Vaccines Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
マラリアワクチンの世界市場-2022-2029
出版日: 2022年10月11日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

主な原動力は、マラリア罹患率の上昇、さまざまなバイオテクノロジー企業や製薬企業による研究開発の増加、マラリアワクチン啓発のための政府主導の増加で、これらが市場成長の原動力になると考えられています。

世界のマラリア罹患率の上昇が市場成長の原動力になると予想されます。

世界的にマラリアの発生件数が増加していることは、予測期間中の市場を後押ししています。例えば、世界保健機関（WHO）によると、2022年に世界で約2億4100万件の症例が観察され、そのうち627万件の死亡が記録されています。アフリカ地域は、2020年に再び世界で最も高いマラリア負担のシェアを示し、95％のマラリア症例と約96％の死亡がこの地域によって占められました。サハラ以南のアフリカでは、毎年約26万人の5歳以下の子供がマラリアによって死亡しており、依然として子供の病気や死亡の最大の原因となっています。

このワクチンは、グラクソ・スミスクライン（GSK）とマラリア・ワクチン・イニシアチブ（MVI）が、ゲイツ・ファミリー財団の資金援助を受けて開発したもので、RTS,Sと呼ばれます。このワクチンは、2021年10月に世界保健機関（WHO）から小児への「広範な使用」が推奨される1stマラリアワクチンです。

R21/Matrix-Mは、最初の研究で77％の有効性が確認された、現在最も効率的なマラリアワクチンです。WHOが求める「75％以上の有効率を持つマラリアワクチン」という条件を満たす初めてのワクチンとなります。オックスフォード大学、ロンドン衛生熱帯医学大学院、ケニア医学研究所、インド血清研究所、ノババックス、ブルキナファソのナノロ保健科学研究所の協力で作成されました。RTS,Sワクチンと比較して、このR21ワクチンはcircumsporozoite protein（CSP）抗原の割合をより多く利用しています。

マラリアワクチン製造に関連する制約が市場成長の妨げとなる

開発者の不足、伝統的な市場の不足、ワクチン対抗寄生虫を作成する技術的な難しさは、マラリアワクチンの生産のための課題となりえます。2021年10月にCentre for diseaese control and preventionが発表した報告書では、「マラリア原虫の遺伝子の複雑さにより、何千もの抗原の可能性がある」と述べられています。マラリア原虫との遭遇は、すでに有効な予防接種がある疾患とは対照的に、生涯免疫を与えるものではありません。"と述べています。したがって、上記の記述から、予測期間中に市場が阻害されることが予想されます。

世界のマラリアワクチン市場レポートでは、約40以上の市場データ表、45以上の図、200ページ（概算）の範囲でのアクセスを提供することになります。

目次

第1章 市場調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場インパクトファクター
    • 促進要因
      • バイオ医薬品企業や製薬企業別研究開発の活発化
    • 抑制要因
      • マラリアワクチンに関連する制限
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース
  • アンメットニーズ
  • 疫学
  • サプライチェーン分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 感染症タイプ別

  • 熱帯熱マラリア原虫
  • アノフェレス属の種
  • P. vivax
  • P.マラリア
  • その他

第8章 ワクチンの種類別

  • 赤芽球性
  • 赤血球生成促進剤
  • 多抗原
  • その他

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 小売薬局
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第12章 企業プロファイル

  • GlaxoSmithKline Biologicals（GSK）
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Sanaria
  • Nobelpharma
  • The Swiss Serum Institute
  • VLP Therapeutics LLC
  • Serum Institute of India
  • CellFree Sciences
  • Novavax
  • Bharat Biotech
  • Kenya medical research institute

第13章 マラリアワクチンの世界市場-DataM

目次
Product Code: DMPH884

Market Overview

Malaria Vaccines Market size was valued at US$ 33.29 million in 2021 and is estimated to reach US$ 327.41 million by 2029, growing at a CAGR of 31.85% during the forecast period (2022-2029).

Malaria an intermittent and remittent fever caused by a protozoan parasite that invades the red blood cells and is transmitted by mosquitoes in many tropical and subtropical regions and leads to severe illness in both pediatrics and adults. Malaria often causes severe disease, including shivering chills, high fevers, and flu-like symptoms. Humans are infected by four different types of malaria parasites Plasmodium falciparum, species of Anopheles, P. ovale, P. vivax, and P. malaria. Malaria vaccines are considered amongst the most important modalities for the prevention of malaria disease and the reduction of malaria transmission.

Market Dynamics

The major driving forces are the rising incidence of malaria cases, increase in research and development by various biotechnology or pharmaceutical companies and increasing government initiatives for malaria vaccines awareness are expected to drive market growth.

The rising incidences of malaria globally is expected to drive the market growth

The rising incidences of malaria cases globally are boosting the market over the forecast period. For instance, according to the World Health Organisation, around 241 million cases were observed globally out of which 6,27,000 deaths were recorded in 2022. African region again shows highest malaria burden share globally in 2020, 95% malaria cases with around 96% deaths were accounted by this region. In sub-Saharan Africa, it continues to be greatest cause of sickness and mortality in children as it claims around 260,000 lifes of African kids every year with age around 5 years or below.

The most recent recombinant vaccine to be created was RTS,S, which was created by GlaxoSmithKline (GSK) and Malaria Vaccine Initiatives (MVI) with funding from the the Gates Family Foundation. The vaccine is the 1st malaria vaccine to be recommended for "wide use" in children by World Health Organization in October 2021.

R21/Matrix-M is currently the most efficient malaria vaccine, with first studies showing 77% efficacy. This is the first vaccination that satisfies the WHO's requirement for a malaria vaccine to have at least a 75% effectiveness rate. The University of Oxford, London School of Hygiene and Tropical Medicine, Kenya Medical Research Institute, Serum Institute of India, Novavax and Institute of Research in Health Sciences in Nanoro, Burkina Faso collaborated to create it. Compared to the RTS,S vaccine, this R21 vaccine utilizes a larger proportion of the circumsporozoite protein (CSP) antigen.

The limitations associated with the malaria vaccines production will hamper the growth of the market

The scarcity of developers, traditional market's lack and the technical difficulty of creating a vaccine counter parasite can be the challenges for the production of a malaria vaccine. In October 2021 the Centre for diseaese control and prevention published a report where they stated that "The genetic complexity of malaria parasites results in thousands of possible antigens. Encounter with plasmodium parasites does not provide lifetime immunity, in contrast to diseases for which there are already effective vaccinations." Therefore, from the above statements, the market is expected to get hampered in the forecast period.

Segment Analysis

The plasmodium falciparum segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The plasmodium falciparum segment is expected to boost the global malaria vaccine market, owing to the increased number of incidences leading to growing research activities. Due to the high incidence by Plasmodium falciparum malaria infection cases, it is anticipated to maintain a dominating position in the worldwide malaria vaccines market in forecasr period. For instance, plasmodium falciparum infection is responsible for more than 90% of malaria fatality worldwide, according to data from the National Center for Biotechnology Information published in August 2021, and thus continues to pose a serious threat to public health on a global scale. RTS,S/AS01 is the potential vaccine for P. falciparum malaria prevention that has undergone the most extensive testing; it targets immune responses against primary circumsporozoite protein (PfCSP) that covers the infecting sporozoite's surface.

Geographical Analysis

North America region holds the largest market share of the global malaria vaccines market

North America dominates the market for malaria vaccine and is expected to show a similar trend over the forecast period owing to the rising incidences of malaria and the rapid research and development of innovative, advanced vaccines development for malaria. According to Pan America Health Organization (PAHO) report 2022, around 600,000 cases of malaria were reported in 2020 by 18 endemic American countries. That shows reduction of 26% from last year. In 2018 Paraguay, got malaria-free certification and El Salvador also received malaria-free certification in 2021.

Ongoing research and development activities are expected to boost the market. For instance, in Dec 2021, VLP Therapeutics Inc., biotech company that is based in United States collaborated for infectious disease vaccination manufacturing and distribution with Nobelpharma Ltd.

Competitive Landscape

The malaria vaccines market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Major key players in malaria vaccines market are GlaxoSmithKline Biologicals (GSK), the Swiss Serum Institute, WRAIR, Sanaria, BioNTech, Nobelpharma, CellFree Sciences, Sumaya Biotech, VLP Therapeutics LLC, Bharat Biotech, Serum Institute of India, Novavax, Kenya medical research institute. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Malaria Vaccines market globally. For instance, in Sep 2021, Serum Institute of India subsidiary, Serum Institute Life Sciences announced its alliance with Biocon Biologics Limited. Under this alliance they will manufacture and commercialize variety of vaccines and antibodies targeting infectious diseases.

In Jun, 2022, BioNTech announced the initiation of construction of its first African facility for manufacturing of m-RNA Vaccine. They will manufacture m-RNA vaccines along with the development of malaria vaccine candidate.

GlaxoSmithKline Biologicals:

Overview:

GSK is a multinational biopharmaceutical business with the aspiration and mission to combine talent, science, and technology in order to conquer disease. They concentrate on four treatment fields: cancer, immunology, oncological disorders, and HIV. Prioritizing vaccination and specialty drug innovation will maximize the growing prospects for disease prevention and treatment.

Product Portfolio:

RTS, S/AS01 (Mosquirix): This is a recombinant vaccine for malaria that was created utilizing DNA from outer glycoprotein of the malaria parasite known as P. falciparum, a part of the hepatitis B virus, and an adjuvant to stimulate the immune system. Mosquirix is its name for commercial purpose. Elevated antibody titers that stop the parasite from invading the liver and helps to avoid infection.

Key Developments: In Oct 2021, Mosquirix vaccine became the first malarial vaccine to be recommended for "wide use" in children by World Health Organization.

The global malaria vaccines market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increase in research and development by biopharmaceutical and pharmaceutical companies
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations associated with the malaria vaccines
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Epidemiology
  • 5.4. Supply chain Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type of infectious agents

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 7.1.2. Market Attractiveness Index, By Type of infectious agents
  • 7.2. Plasmodium Falciparum
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Species of Anopheles
  • 7.4. P. vivax
  • 7.5. P. malaria
  • 7.6. Others

8. By Type of Vaccines

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 8.1.2. Market Attractiveness Index, By Type of vaccines
  • 8.2. Erythrocytic
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Pre erythrocytic
  • 8.4. Multi antigen
  • 8.5. Others

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Specialty Clinics
  • 9.4. Retail Pharmacy
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Vaccines
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. GlaxoSmithKline Biologicals (GSK)
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanaria
  • 12.3. Nobelpharma
  • 12.4. The Swiss Serum Institute
  • 12.5. VLP Therapeutics LLC
  • 12.6. Serum Institute of India
  • 12.7. CellFree Sciences
  • 12.8. Novavax
  • 12.9. Bharat Biotech
  • 12.10. Kenya medical research institute

LIST NOT EXHAUSTIVE

13. Global Malaria Vaccines Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us